EA199600018A2 - Сконденсированные гексациклические соединения и способы их получения - Google Patents

Сконденсированные гексациклические соединения и способы их получения

Info

Publication number
EA199600018A2
EA199600018A2 EA199600018A EA199600018A EA199600018A2 EA 199600018 A2 EA199600018 A2 EA 199600018A2 EA 199600018 A EA199600018 A EA 199600018A EA 199600018 A EA199600018 A EA 199600018A EA 199600018 A2 EA199600018 A2 EA 199600018A2
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
camthothecin
derivative
antitumour activity
formula
Prior art date
Application number
EA199600018A
Other languages
English (en)
Other versions
EA199600018A3 (ru
EA000036B1 (ru
Inventor
Синдзи Камихара
Казуаки Канаи
Сигеру Ногути
Хирофуми Терасава
Хироаки Китаока
Original Assignee
Дайити Фармасьютикал Ко., Лтд.
Кабусики Кайся Якулт Хонса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайити Фармасьютикал Ко., Лтд., Кабусики Кайся Якулт Хонса filed Critical Дайити Фармасьютикал Ко., Лтд.
Publication of EA199600018A2 publication Critical patent/EA199600018A2/ru
Publication of EA199600018A3 publication Critical patent/EA199600018A3/ru
Publication of EA000036B1 publication Critical patent/EA000036B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Изобретение относится к производному камптотецина формулы (1), обладающему противоопухолевой активностью, и к способу получения этого соединения, который включает обработку соединения формулы (2) метансульфоновой кислотой и последующую перекристаллизацию полученного продукта:Изобретение относится также к фармацевтической композиции, содержащей соединение формулы I или его гидрат и фармацевтически приемлемую соль.
EA199600018A 1995-04-10 1996-04-09 Метансульфонат производного камптотецина, способы его получения и фармацевтическая композиция на его основе EA000036B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8371795 1995-04-10

Publications (3)

Publication Number Publication Date
EA199600018A2 true EA199600018A2 (ru) 1996-10-01
EA199600018A3 EA199600018A3 (ru) 1997-03-31
EA000036B1 EA000036B1 (ru) 1998-02-26

Family

ID=13810270

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199600018A EA000036B1 (ru) 1995-04-10 1996-04-09 Метансульфонат производного камптотецина, способы его получения и фармацевтическая композиция на его основе

Country Status (13)

Country Link
US (2) US6504029B1 (ru)
EP (1) EP0737686B1 (ru)
KR (1) KR100400941B1 (ru)
CN (1) CN1050131C (ru)
AT (1) ATE181919T1 (ru)
CA (1) CA2173671A1 (ru)
DE (1) DE69603117T2 (ru)
DK (1) DK0737686T3 (ru)
EA (1) EA000036B1 (ru)
ES (1) ES2136338T3 (ru)
GR (1) GR3031400T3 (ru)
NO (1) NO314085B1 (ru)
TW (1) TW382630B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU64602A (sh) 2000-02-28 2005-06-10 Aventis Pharma S.A. Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
EP1333820A2 (en) 2000-10-27 2003-08-13 Aventis Pharma S.A. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
US20090104254A1 (en) 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
WO2012050591A1 (en) 2010-10-15 2012-04-19 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
WO2007113687A2 (en) 2006-03-30 2007-10-11 Diatos S.A. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
JP5793084B2 (ja) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー プリンヌクレオシドの合成
PT2552930E (pt) 2010-03-31 2015-11-17 Gilead Pharmasset Llc 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin- 1-(2h)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2- il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropilo cristalino
SI2907824T1 (en) * 2012-10-11 2018-06-29 Daiichi Sankyo Company, Limited THE HEALTHY KJUBIER OF THE PROTITEL
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
KR102088169B1 (ko) 2013-12-25 2020-03-12 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
KR102190548B1 (ko) 2014-01-31 2020-12-14 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
KR20240008415A (ko) 2014-04-10 2024-01-18 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
EP3552626A4 (en) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
CN110382535A (zh) 2017-01-17 2019-10-25 第一三共株式会社 抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
CN111065621B (zh) 2017-08-31 2024-01-26 第一三共株式会社 制备抗体-药物缀合物的新方法
EP4249002A3 (en) 2018-05-18 2023-11-22 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
US20210353764A1 (en) 2018-09-26 2021-11-18 Jiangsu Hengrui Medicine Co., Ltd. Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
BR112021004829A2 (pt) 2018-09-30 2021-06-08 Jiangsu Hengrui Medicine Co., Ltd. conjugado de anticorpo anti-b7h3-análogo de exatecano e uso medicinal do mesmo
HUE060364T2 (hu) 2019-03-29 2023-02-28 Medimmune Ltd Vegyületek és konjugátumaik
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
BR112022011032A2 (pt) 2019-12-12 2022-08-16 Jiangsu Hengrui Medicine Co Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
CN114846021B (zh) 2020-01-22 2024-06-14 江苏恒瑞医药股份有限公司 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
CN115103691A (zh) 2020-03-25 2022-09-23 江苏恒瑞医药股份有限公司 一种含抗体药物偶联物的药物组合物及其用途
JP2023521956A (ja) 2020-03-25 2023-05-26 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体の調製方法
CN115298186A (zh) 2020-03-25 2022-11-04 江苏恒瑞医药股份有限公司 抗psma抗体-依喜替康类似物偶联物及其医药用途
WO2023030364A1 (zh) * 2021-09-01 2023-03-09 上海弼领生物技术有限公司 一种喜树碱类化合物、其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6087746A (ja) * 1983-10-17 1985-05-17 Hakubakumai Kk 即席麺ないしは焼そば用蒸し麺の製造方法
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
US5637770A (en) * 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
GB9319944D0 (en) * 1993-09-28 1993-11-17 Erba Carlo Spa Process for the preparation of 9-amino camptothecin

Also Published As

Publication number Publication date
KR960037682A (ko) 1996-11-19
EA199600018A3 (ru) 1997-03-31
AU692078B2 (en) 1998-05-28
NO314085B1 (no) 2003-01-27
ES2136338T3 (es) 1999-11-16
GR3031400T3 (en) 2000-01-31
US20010034446A1 (en) 2001-10-25
ATE181919T1 (de) 1999-07-15
DE69603117T2 (de) 1999-10-28
EP0737686B1 (en) 1999-07-07
KR100400941B1 (ko) 2003-12-24
DE69603117D1 (de) 1999-08-12
CN1050131C (zh) 2000-03-08
EP0737686A1 (en) 1996-10-16
US6504029B1 (en) 2003-01-07
EA000036B1 (ru) 1998-02-26
NO961405L (no) 1996-10-11
US6552197B2 (en) 2003-04-22
DK0737686T3 (da) 1999-11-22
TW382630B (en) 2000-02-21
NO961405D0 (no) 1996-04-09
AU5056696A (en) 1996-10-24
CA2173671A1 (en) 1996-10-11
CN1133290A (zh) 1996-10-16

Similar Documents

Publication Publication Date Title
GR3031400T3 (en) Camthothecin derivative with antitumour activity
Gibson et al. Selective removal of an N-BOC protecting group in the presence of a tert-butyl ester and other acid-sensitive groups
HUT52043A (en) Process for producing intermediates for producing substituted indolinon derivatives
AU5786690A (en) Process for purifying tryptophan
HUT37141A (en) Process for production of substituted 5,11-dihydro-6h-dibenz /b,e/ azepin-6-ons
KR880700793A (ko) 퀴놀린 카복실산의 제조 방법
CA2305580A1 (en) Process for production of substituted alkylamine or its salt
EP0969000A4 (en) PROCESS FOR REDUCING $ g (a) -AMINO CETONES
ES2193524T3 (es) Procedimiento de preparacion de acido azetidino-2-carboxilico.
GR3025213T3 (en) Process for producing a N-phenyl-N-(4-piperidinyl) amide derivative.
DE59406746D1 (de) Verfahren zur herstellung von schwefelsäurehalbestern
CA1273347C (ru)
SE8503811D0 (sv) Novel process for the preparation of an aminolactone
EP1132375A4 (en) AMINOACRYLIC ACID DERIVATIVES AND PROCESS FOR PRODUCING THE SAME
KR0137673B1 (en) Process for preparing sulfonamide derivative of norbornane

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU